p19Arf Antibody
Rat Monoclonal 5.C3.1 IgG2b
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Background
The Ink4a-Arf locus encodes two tumor suppressor proteins, p16Ink4a and p19Arf. Expression of Ink4a and Arf is regulated by distinct promoters upstream of alternative first exons whose products are spliced to a common second exon translated in alternative reading frames (from which Arf gets its name). The two genes are induced by different stress signals and can be separately mutated or silenced in tumor cells. Targeted disruption of either or both genes in mouse leads to spontaneous tumor formation, which is accelerated by exposure of the mutant animals to chemical carcinogens or ionizing radiation. Inactivation of ARF by mutation, deletion, or epigenetic silencing is observed in many human cancers, underscoring the role of this protein as a potent and ubiquitous tumor suppressor. p19Arf is activated by Myc or mutant Ras. Once activated, p19Arf binds to the p53 negative regulator Mdm2, leading to p53 stabilization and unleashing a p53-dependent transcriptional program that triggers either cell cycle arrest or apoptosis. p19Arf also has p53-independent inhibitory effects on cell proliferation. p19Arf is a nucleolar protein and is implicated in ribosomal biogenesis.
Product Details
Target Details
Application Details
Formulation
Shipping & Handling
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
